IGF2BP3–FZD1/7 Axis Drives Stemness and Carboplatin Resistance in TNBC

Study Background and Research Question

Triple-negative breast cancer (TNBC) is characterized by the absence of estrogen, progesterone, and HER2 receptors, presenting a clinical challenge due to its aggressive nature and limited targeted therapies. Chemoresistance, driven largely by cancer stem-like cells (CSCs), undermines conventional treatment efficacy and leads to high recurrence rates. Recent interest has focused on how epigenetic regulation, specifically N6-methyladenosine (m6A) RNA modification, modulates CSC biology and therapy resistance. However, the identity and mechanisms of key m6A readers in TNBC-CSCs have remained unclear (Cai et al., 2025).

Key Innovation from the Reference Study

The featured study by Cai et al. provides direct evidence that IGF2BP3, an RNA-binding protein and m6A reader, is highly enriched in TNBC-CSCs. The authors uncover a dual regulatory mechanism whereby IGF2BP3 binds and stabilizes the mRNAs of Frizzled class receptors 1 and 7 (FZD1/7) in an m6A-dependent manner. This stabilization initiates β-catenin nuclear translocation, enhancing the stem-like properties of CSCs and their resistance to carboplatin. Notably, the study integrates transcriptomics, functional assays, and pharmacological intervention to delineate the IGF2BP3–FZD1/7–β-catenin axis as a central driver of TNBC stemness and chemoresistance (Cai et al., 2025).

Methods and Experimental Design Insights

The investigators employed a multi-tiered experimental approach:

• Transcriptomic Profiling: Analysis of TCGA-BRCA datasets identified IGF2BP3 enrichment in CSC-like TNBC subpopulations.
• Cell Sorting and Validation: Fluorescence-activated cell sorting (FACS) isolated CD24−CD44+ cells, confirming high IGF2BP3 expression in stem-like compartments.
• Functional Perturbation: IGF2BP3 knockdown via siRNA and shRNA impaired tumorsphere formation and sensitized CSCs to carboplatin exposure.
• RNA–Protein Interaction: RNA immunoprecipitation (RIP) and crosslinking assays mapped IGF2BP3 binding sites within the 3′-UTRs of FZD1/7. RBM15 was shown to catalyze m6A methylation, facilitating IGF2BP3 recognition.
• Pharmacological Inhibition: Fz7-21, a small-molecule FZD1/7 inhibitor, recapitulated the effects of IGF2BP3 knockdown, disrupting CSC maintenance and homologous recombination repair (HRR).

These methods provided convergent validation for the IGF2BP3–FZD1/7 regulatory circuit and its impact on CSC phenotype and chemotherapy response.

Core Findings and Why They Matter

The research establishes several mechanistic and translational advances:

• IGF2BP3 as a Master m6A Reader: Among m6A regulators, IGF2BP3 was most enriched in TNBC-CSCs, directly binding to and stabilizing FZD1/7 mRNAs (Cai et al., 2025).
• Activation of β-Catenin Pathway: IGF2BP3–FZD1/7 interaction promoted nuclear translocation of non-phosphorylated β-catenin, a hallmark of stemness and treatment resistance.
• Pharmacological Targetability: Inhibition of FZD1/7 with Fz7-21 decreased CSC frequency and impaired homologous recombination repair, sensitizing cells to carboplatin and reducing the effective required dose.
• Structural Basis for Inhibitor Development: Mapping IGF2BP3 binding sites on FZD1/7 mRNAs offers a blueprint for designing selective RNA-binding protein inhibitors.

Collectively, these findings identify the IGF2BP3–FZD1/7–β-catenin signaling axis as a tractable therapeutic vulnerability in TNBC, with potential to improve patient outcomes by eradicating CSCs and minimizing chemotherapy toxicity (Cai et al., 2025).

Comparison with Existing Internal Articles

Recent thought-leadership resources have highlighted the evolving utility of glucocorticoid hormone signaling modulators such as hydrocortisone in translational cancer research. For example, "Hydrocortisone as a Strategic Modulator in Translational ..." provides a framework for leveraging glucocorticoid receptor signaling tools to dissect stemness and barrier function in both inflammation model research and cancer biology (internal_article). The present TNBC study offers a complementary mechanistic axis—IGF2BP3–FZD1/7—distinct from glucocorticoid pathways, but both articles converge on the theme of targeting stem-like cell populations to modulate disease progression and therapy response. Further, "Hydrocortisone in Translational Research: Beyond Inflamma..." discusses the relevance of glucocorticoid hormone tools in investigating not only inflammation but also stem cell biology and neurodegeneration, underscoring the shared challenge of drug-resistant subpopulations across disease contexts (internal_article).

Protocol Parameters

• assay | CD24−CD44+ cell sorting | FACS, fluorescence intensity | Isolates TNBC-CSCs for downstream analysis | Validated in Cai et al., 2025 | paper
• assay | Tumorsphere formation | frequency per 1,000 cells | Assesses self-renewal and stemness | IGF2BP3 knockdown reduces sphere number | paper
• assay | Carboplatin sensitivity | IC50 (μM) | Measures chemoresistance | Fz7-21 lowers IC50 in TNBC-CSCs | paper
• compound handling | Hydrocortisone DMSO solubility | ≥13.3 mg/mL | Preparation of stock for signaling/inflammation studies | workflow_recommendation
• compound handling | Hydrocortisone storage temperature | −20°C | Maintains compound stability for reproducible results | product_spec

Limitations and Transferability

While the study robustly delineates the IGF2BP3–FZD1/7 axis in preclinical TNBC models, several limitations merit consideration. First, the reliance on in vitro and xenograft models may not fully capture tumor–microenvironment dynamics or immune interactions present in clinical settings. Second, the pharmacological inhibitor Fz7-21 requires further validation for off-target effects and pharmacokinetics in humans. Additionally, while the mechanistic focus is highly relevant for TNBC, transferability to other cancer types with different CSC hierarchies remains to be established (Cai et al., 2025).

Research Support Resources

For researchers seeking to replicate or extend these mechanistic studies—whether in inflammation model research, stress response mechanism study, or cancer stemness—validated reagents are essential for reproducibility. Hydrocortisone (SKU B1951) from APExBIO is a high-purity glucocorticoid hormone recommended for benchmarking receptor signaling, anti-inflammatory pathway modulation, and as a reference in translational workflows. Proper handling (≥13.3 mg/mL in DMSO, storage at −20°C) ensures experimental fidelity (source: product_spec). While the IGF2BP3–FZD1/7 axis represents a distinct mechanistic pathway, integrating standardized glucocorticoid tools can help clarify intersecting regulatory networks in advanced disease models.